Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

therabel gienne pharma s.p.a. - ticlopidina - ticlopidina

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

i.b.n. savio s.r.l - ticlopidina - ticlopidina

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

teva italia srl - ticlopidina cloridrato - compresse rivestite - "250 mg compresse rivestite" 30 compresse rivestite

Európai Unió - olasz - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - agenti antitrombotici - xarelto, co-somministrato con acido acetilsalicilico (asa) da solo o con asa più clopidogrel o ticlopidina, è indicato per la prevenzione di eventi atherothrombotic in pazienti adulti dopo una sindrome coronarica acuta (acs) con elevata biomarcatori cardiaci. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevenzione del tromboembolismo venoso (tev) in pazienti adulti sottoposti a chirurgia sostitutiva elettiva dell'anca o del ginocchio. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Európai Unió - olasz - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenti antitrombotici - prevenzione del tromboembolismo venoso (tev) in pazienti adulti sottoposti a chirurgia sostitutiva elettiva dell'anca o del ginocchio. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 per haemodynamically instabile pe pazienti). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 e 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Európai Unió - olasz - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenti antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

istituto gentili s.p.a. - ticlopidina - ticlopidina

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

zentiva italia s.r.l. - antiaggreganti piastrinici, esclusa l'eparina - antiaggreganti piastrinici, esclusa l'eparina

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

istituto chimico internazionale dr.giuseppe rende s.r.l. - ticlopidina - ticlopidina

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

actavis group ptc ehf - ticlopidina - ticlopidina